Dashboard
Manage Tickers

NVSNOVARTIS AG

NYSE novartis.com


$ 120.85 $ 0.47 (0.39 %)    

Friday, 30-Aug-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 120.89
$ 120.83 x 100
$ 120.87 x 100
-- - --
$ 88.80 - $ 120.92
902,659
na
247.1B
$ 0.57
$ 16.64
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

novartis-cholesterol-lowering-drug-shows-encouraging-outcome-in-late-stage-study
Novartis' Cholesterol-Lowering Drug Shows ...
08/28/2024 13:33:36

Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate AS...

novartis-pharma-ag-a-subsidiary-of-novartis-inked-a-exclusive-global-licensing-agreement-and-strategic-collaboration-with-lindy-biosciences-for-multi-target-drug-delivery-innovation
Novartis Pharma AG, A Subsidiary Of Novart...
08/28/2024 11:00:01

novartis-phase-3-v-mono-study-for-twice-yearly-leqvio-inclisiran-met-its-primary-endpoints-showing-leqvio-monotherapy-lowered-low-density-lipoprotein-cholesterol-versus-placebo-and-ezetimibe-in-patients-who-were-at-low-or-moderate-risk-of-developing-atherosclerotic-cardiovascular-disease-and-not-receiving-lipid-lowering-therapy
Novartis' Phase 3 V MONO Study For Twice-y...
08/28/2024 10:13:50

siemens-healthineers-to-buy-novartis-diagnostics-to-bolster-cancer-scan-business-in-220m-deal
Siemens Healthineers To Buy Novartis Diagn...
08/26/2024 12:54:18

Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemi...

judge-rules-against-novartis-effort-to-halt-generic-launch-of-its-top-selling-heart-disease-drug
Judge Rules Against Novartis' Effort To Ha...
08/13/2024 14:32:11

Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-s...

fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease
FDA Approves Expanded Use Of Novartis' Rar...
08/08/2024 13:52:47

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropat...

us-fda-approves-novartis-fabhalta-for-reducing-proteinuria-in-adults-with-primary-immunoglobulin-a-nephropathy-igan
US FDA Approves Novartis' Fabhalta For Red...
08/07/2024 18:22:21

- Reuters 

novartis-and-viatris-sued-over-unlawful-use-of-hela-cells-used-for-cancer-treatment-drugs
Novartis And Viatris Sued Over Unlawful Us...
08/06/2024 17:48:49

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks prof...

novartis-scemblix-granted-fda-priority-review-for-the-treatment-of-adults-with-newly-diagnosed-cml
Novartis Scemblix Granted FDA Priority Rev...
07/29/2024 16:10:34

https://www.novartis.com/news/media-releases/novartis-scemblix-granted-fda-priority-review-treatment-adults-newly-diagnosed-cml...

watching-novartis-traders-circulating-the-co-lost-a-ruling-from-fda-allowing-for-generic-ernestro
Watching Novartis; Traders Circulating The...
07/24/2024 19:44:40

dren-bio-announces-strategic-collaboration-with-novartis-to-develop-novel-targeted-myeloid-engagers-for-cancer-dren-bio-to-receive-total-upfront-consideration-of-150m-and-is-eligible-to-receive-milestone-payments-and-tiered-royalties
Dren Bio Announces Strategic Collaboration...
07/24/2024 12:25:24

– Collaboration combines Dren's targeted cell depletion platform with Novartis research, development and commercial experti...

astrazeneca-sanofi-and-other-pharma-giants-pursue-chinese-deals-despite-rising-us-china-strife
AstraZeneca, Sanofi And Other Pharma Giant...
07/23/2024 07:42:37

The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.

vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-loss-giants-eli-lilly-novo-tumble-whats-driving-markets-thursday
VIX Stages Double-Digit Spike As Risk Off ...
07/18/2024 18:05:28

It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), ofte...

novartis-q2-earnings-revenue-and-eps-beat-raises-2024-profit-forecast-on-strong-demand-for-key-drugs
Novartis' Q2 Earnings: Revenue And EPS Bea...
07/18/2024 13:06:15

Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers inc...

wall-street-gearing-up-for-tech-led-rebound-ahead-of-netflix-earnings-economist-expects-soft-landing-but-says-brace-for-bigger-fed-rate-cuts-if-this-happens
Wall Street Gearing Up For Tech-Led Reboun...
07/18/2024 11:34:56

Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong ...

dr-horton-netflix-and-3-stocks-to-watch-heading-into-thursday
D.R. Horton, Netflix And 3 Stocks To Watch...
07/18/2024 07:05:12

novartis-now-expects-2024-net-sales-to-grow-high-single-to-low-double-digit-and-core-operating-income-to-grow-mid--to-high-teens-prior-low-double-digit-to-mid-teens
Novartis Now Expects 2024 Net Sales To Gro...
07/18/2024 05:23:17

novartis-q2-2024-adj-eps-197-beats-189-estimate-sales-12512b-beat-12375b-estimate
Novartis Q2 2024 Adj EPS $1.97 Beats $1.89...
07/18/2024 05:20:09

Novartis (NYSE:NVS) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.89 by 4.23 p...

netflix-goldman-sachs-jj-asml-lead-q2-reports-this-week-as-analysts-see-earnings-growth-accelerating-to-fastest-in-over-2-years
Netflix, Goldman Sachs, J&J, ASML Lead Q2 ...
07/15/2024 09:13:17

Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the tre...

ozempic-maker-novo-nordisk-reprimanded-by-uk-regulators-for-payment-disclosure-failures
Ozempic Maker Novo Nordisk Reprimanded by ...
07/05/2024 16:28:59

UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION